Lactobacillus plantarum capable of resisting various drug-resistant bacteria and application of lactobacillus plantarum
Lactiplantibacillus plantarum 6-14, isolated from wild bird stool, solved the problem of inhibition of a variety of drug-resistant bacteria, provided acid resistance and bile salt resistance, and was used to prepare antibacterial microbial preparations, significantly inhibiting multiple drugs. These drugs-resistant and non-resistant bacteria improve the immune function and growth performance of animals.
Patent Information
- Application Number
- CN202411069781.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-06
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-08-06
AI Technical Summary
With the widespread use of antibiotics, more and more bacteria have developed drug resistance. The prior art is difficult to effectively inhibit the growth of a variety of drug-resistant bacteria, threatening the safety of animals and humans.
Lactiplantibacillus plantarum 6-14, isolated from wild bird stools, is used. This strain has inhibitory effects on a variety of drug-resistant and non-resistant bacteria, and is acid-resistant and bile-salt-resistant. It is used to prepare antibacterial microorganisms. Formulations, including oral and topical preparations, probiotic and microbial preparations for animals.
Lactobacillus plantarum 6-14 significantly inhibits a variety of drug-resistant and non-resistant bacteria such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecalis, penicillin-resistant Streptococcus pneumoniae, and provides broad-spectrum antibacterial activity. Laying the foundation for the development of antibacterial probiotic preparations, it improves the immune function and growth performance of animals.
Smart Images

Figure CN118909856A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of microorganisms, and particularly relates to a plant lactobacillus resistant to multiple drug-resistant bacteria and an application thereof. Background Art
[0002] People have long discovered that some microorganisms have an inhibitory effect on the growth and reproduction of other microorganisms. With the development of science, people have finally revealed its essence and found substances in some microorganisms that have the effect of inhibiting the growth and reproduction of other microorganisms. These substances are called antibiotics, such as penicillin produced by Penicillium and streptomycin produced by Streptomyces griseus. After the 1990s, scientists expanded the scope of antibiotics and collectively referred to them as biopharmaceuticals. They are mainly used to treat various bacterial infections or pathogenic microbial infections, and generally do not have serious side effects on their hosts. However, with the widespread use of antibiotics, more and more bacteria have developed drug resistance, which seriously threatens the safety of animals and humans, and antibiotic substitutes have also emerged. So far, many antibiotic substitutes have been discovered, mainly microecological preparations, oligosaccharides, antimicrobial peptides, enzyme preparations, Chinese herbal preparations, acidifiers, etc. At present, it is generally recognized that the most promising is microecological preparations.
[0003] Probiotic preparations are live bacteria preparations for animals made from known beneficial microorganisms through special processes such as cultivation, extraction, and drying. Probiotic preparations can participate in regulating the microecological balance in the gastrointestinal tract, stimulate specific or nonspecific immune functions, help promote animal growth, enhance animal immune function, and improve the internal and external ecological environment. Summary of the invention
[0004] The purpose of this section is to summarize some aspects of embodiments of the present invention and to briefly introduce some preferred embodiments.
[0005] The plant lactobacillus (Lactiplantibacillus plantarum) 6-14 of the present invention is deposited in the Guangdong Microbiological Culture Collection Center, with a deposit number of GDMCC No. 64771, a deposit date of June 20, 2024, and an address of the Institute of Microbiology, Guangdong Academy of Sciences, 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou.
[0006] As one aspect of the present invention, the present invention provides a Lactobacillus plantarum 6-14 resistant to multiple drug-resistant bacteria, characterized in that: the Lactobacillus plantarum 6-14 is deposited under the GDMCC No: 64771.
[0007] The present invention also provides the use of the Lactobacillus plantarum 6-14 resistant to multiple drug-resistant bacteria in the preparation of a probiotic preparation.
[0008] The present invention also provides the use of the Lactobacillus plantarum 6-14 resistant to multiple drug-resistant bacteria in the preparation of a microbial preparation with an antibacterial effect, characterized in that the antibacterial effect includes inhibiting drug-resistant bacteria and / or non-drug-resistant bacteria.
[0009] The antibacterial effect includes inhibiting one or more of methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecalis, penicillin-resistant Streptococcus pneumoniae, Staphylococcus aureus, Escherichia coli, Salmonella enteritidis, and Salmonella typhimurium.
[0010] Wherein, the microbial preparation includes a microbial preparation for animals.
[0011] Wherein, the animals include poultry, livestock or pets.
[0012] Wherein: the microbial preparation includes oral preparation and / or external preparation.
[0013] Wherein, the Lactobacillus plantarum 6-14 is acid-resistant.
[0014] Wherein, the Lactobacillus plantarum 6-14 has bile salt resistance.
[0015] Beneficial effects of the present invention: the present invention isolates a strain of Lactobacillus plantarum 6-14 from the collected wild bird feces, and the strain has a significant inhibitory effect on a variety of drug-resistant bacteria and non-drug-resistant bacteria. The Lactobacillus plantarum 6-14 involved in the present invention has a broad-spectrum antibacterial activity, and Lactobacillus plantarum 6-14 can resist drug-resistant bacteria and non-drug-resistant bacteria. Drug-resistant bacteria include: methicillin-resistant Staphylococcus aureus (ATCC43300), vancomycin-resistant Enterococcus faecalis (ATCC51299), and penicillin-resistant Streptococcus pneumoniae (ATCC51915); non-drug-resistant bacteria include: Staphylococcus aureus (ATCC25923), Escherichia coli (ATCC25922), Salmonella enteritidis (ATCC19585), and Salmonella typhimurium (CVCC542). The present invention lays a foundation for the development of good antibacterial probiotic preparations. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] In order to more clearly illustrate the technical solution of the embodiment of the present invention, the following briefly introduces the drawings required for describing the embodiment, wherein:
[0017] Figure 1 This is the colony morphology of Lactobacillus plantarum 6-14.
[0018] Figure 2 This is the Gram-stained bacterial morphology of Lactobacillus plantarum 6-14.
[0019] Figure 3 This is the colony morphology of Lactobacillus plantarum 6-14 on a blood agar plate.
[0020] Figure 4 This is the electrophoresis identification diagram of 16s rRNA of Lactobacillus plantarum 6-14.
[0021] Figure 5 This is a comparison chart of the inhibition rings of Lactobacillus plantarum 6-14 and the other two strains of Lactobacillus plantarum against drug-resistant bacteria.
[0022] Figure 6 This is a comparison chart of the inhibition rings of Lactobacillus plantarum 6-14 and the other two strains of Lactobacillus plantarum against non-resistant bacteria.
[0023] Figure 7 This is the result of the drug sensitivity test of Lactobacillus plantarum 6-14. DETAILED DESCRIPTION
[0024] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the specific implementation methods of the present invention are described in detail below in conjunction with specific embodiments.
[0025] Embodiment 1:
[0026] Isolation and purification of strains
[0027] 1. Sample source
[0028] The strain used in the present invention was isolated from wild bird feces. A total of more than 60 samples were collected for subsequent separation, purification and identification.
[0029] 2. Isolation and Purification of Strains
[0030] Use a sterile cotton swab to dip an appropriate amount of feces into an EP tube, and immediately send it to the laboratory for strain isolation. Add MRS liquid culture medium to the EP tube containing feces, vortex mix, and inoculate it into MRS solid culture medium using the streak method on a clean bench, and culture it at 37°C for 18h. After the culture is completed, select typical colonies from the agar medium and perform multiple streak purification in MRA solid culture medium until all colonies in the entire plate have the same morphology. Pick a single colony and culture it in MRS liquid culture medium. The obtained strain is stored in MRS liquid culture medium containing 25% glycerol and stored at -80°C.
[0031] Embodiment 2:
[0032] Oxford cup antibacterial experiment
[0033] The Oxford cup method was used to perform antibacterial experiments on the purified strains. The pathogenic bacteria included methicillin-resistant Staphylococcus aureus (ATCC43300), vancomycin-resistant Enterococcus faecalis (ATCC51299), penicillin-resistant Streptococcus pneumoniae (ATCC51915), Staphylococcus aureus (ATCC25923), Escherichia coli (ATCC25922), Salmonella enteritidis (ATCC19585), and Salmonella typhimurium (CVCC542). The concentration of the probiotic solution was adjusted to 5×10 8 CFU / ml, centrifuge and adjust the concentration of pathogenic bacteria to 10 5 -10 6 CFU / ml, 100 μl of pathogenic bacteria liquid was evenly spread on LB solid medium, an Oxford cup was placed on the medium, 200 μl of probiotic liquid supernatant was pipetted into the Oxford cup. Incubate at 37℃ for 18h, and measure the diameter of the inhibition zone (Table 1).
[0034] Table 1 Diameter of antibacterial ring in Oxford cup antibacterial test (mm)
[0035]
[0036]
[0037] Strain 6-14 with the best antibacterial effect on the above pathogens was selected. The selected strain 6-14 was sequenced with universal bacterial primers 16s rRNA. It was identified that the strain belongs to Lactobacillus plantarum and is preserved in Guangdong Microbial Culture Collection Center, with the preservation number: GDMCC No: 64771, the preservation date: June 20, 2024, and the address: Institute of Microbiology, Guangdong Academy of Sciences, 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou.
[0038] Embodiment 3:
[0039] Analysis of stress resistance of Lactobacillus plantarum 6-14
[0040] 1. Acid resistance of Lactobacillus plantarum 6-14
[0041] High pressure PBS was used to adjust the pH to 3.0 with hydrochloric acid to prepare artificial gastric juice. 3 mg of pepsin was added per ml of artificial gastric juice, and the juice was filtered with a 0.22 μm filter. Lactobacillus plantarum 6-14 (1×10 8CFU / ml). The cells were cultured at 37°C and counted at 0, 0.5, 1, 2, and 3 hours to calculate their survival rates. The results are shown in Table 2. The survival rate of Lactobacillus plantarum 6-14 was 76.3% after being treated in artificial gastric juice at pH 3.0 for 3 hours, which was significantly higher than that of the other two strains of Lactobacillus plantarum (65.6% and 43.2%), indicating that Lactobacillus plantarum 6-14 has better acid resistance.
[0042] Table 2 Stress resistance of Lactobacillus plantarum 6-14 under acidic conditions
[0043]
[0044]
[0045] 2. Bile salt tolerance of Lactobacillus plantarum 6-14
[0046] Prepare MRS liquid medium containing 0.3% bile salts, add 3 mg of porcine bile salts per ml of high pressure medium, filter with a 0.22 μm filter, and add Lactobacillus plantarum 6-14 (1×10 8 CFU / ml). The cells were cultured at 37°C and counted at 0, 0.5, 1, 2, and 3 hours to calculate their survival rates. The results are shown in Table 3. The survival rate of Lactobacillus plantarum 6-14 after 3 hours in MRS liquid culture containing 0.3% bile salts was 60.2%, which was significantly higher than that of the other two strains of Lactobacillus plantarum (50.6% and 40.0%), indicating that Lactobacillus plantarum 6-14 has a certain bile salt tolerance.
[0047] Table 3 Stress resistance of Lactobacillus plantarum 6-14 under bile salt conditions
[0048] Strain name 0.5h survival rate 1h survival rate 2h survival rate 3h survival rate Lp 6-14 84.2% 79.3% 65.1% 60.2% Lp 8-3 75.8% 60.0% 55.2% 50.6% Lp 7-8 74.7% 61.6% 50.4% 40.0%
[0049] Embodiment 4:
[0050] Safety Analysis of Lactobacillus Plantarum 6-14
[0051] Weigh 3.9g of Columbia agar medium, heat and dissolve in 100ml of distilled water, sterilize at 121℃ for 15 minutes, wait for the medium to cool to about 50℃, add 5% sterile defibrinated sheep blood, mix well, and pour into a sterile plate. Use the three-zone line method to inoculate the bacterial solution into the plate, culture at 37℃ for 18h, and observe the hemolysis. It can be observed that the colony morphology is complete and there is no hemolysis around it.
[0052] Embodiment 5:
[0053] Drug sensitivity test of Lactobacillus plantarum 6-14
[0054] Adjust the concentration of Lactobacillus plantarum 6-14 to 1.5 × 10 8 CFU / ml, adjust the antibiotic concentration: erythromycin (1.5mg / ml), vancomycin (3mg / ml), ampicillin (1mg / ml), tetracycline (3mg / ml). Pipette 100μl of the adjusted bacterial solution and evenly apply it on the MRS solid culture medium, clamp the round filter paper, stick it on the solid culture medium, add 10μl of antibiotics to the filter paper, and culture at 37℃ for 18h, and measure the diameter of the inhibition ring (Table 3).
[0055] Table 3 Antibacterial ring diameter of drug sensitivity test (mm)
[0056] antibiotic name Erythromycin Vancomycin Ampicillin tetracycline Lp 6-14 28±6.5 20±7.5 21±7 27±7
[0057] The above experiments showed that Lactobacillus plantarum 6-14 was sensitive to erythromycin, vancomycin, ampicillin and tetracycline.
[0058] Embodiment 6:
[0059] Application of Lactobacillus plantarum 6-14
[0060] 1. Application in pet food: Make plant lactobacillus 6-14 into freeze-dried bacterial powder and add 2×10 per gram of ordinary dog food. 6 Mix and feed with a ratio of 6-14 CFU active Lactobacillus plantarum.
[0061] 2. Add to pet shower gel: adjust the concentration of Lactobacillus plantarum 6-14 to 1×10 9 CFU / ml, centrifuge to obtain the supernatant, and add the bacterial liquid supernatant to ordinary pet shower gel in a 1:1 ratio.
[0062] It should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solutions of the present invention may be modified or replaced by equivalents without departing from the spirit and scope of the technical solutions of the present invention, which should all be included in the scope of the claims of the present invention.
Claims
1. A Lactobacillus plantarum 6-14 against multiple drug-resistant bacteria, characterized in that: The Lactobacillus plantarum 6-14 is deposited with GDMCC No: 64771.
2. Use of the Lactobacillus plantarum 6-14 against multiple drug-resistant bacteria according to claim 1 in the preparation of a probiotic preparation.
3. The use of Lactobacillus plantarum 6-14 against multiple drug-resistant bacteria according to claim 1 in the preparation of a microbial preparation with antibacterial effect, characterized in that: The antibacterial effect includes inhibiting drug-resistant bacteria and / or non-drug-resistant bacteria.
4. The use according to claim 3, characterized in that: The antibacterial effect includes inhibiting one or more of methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecalis, penicillin-resistant Streptococcus pneumoniae, Staphylococcus aureus, Escherichia coli, Salmonella enteritidis, and Salmonella typhimurium.
5. The use according to claim 3, characterized in that: The microbial preparations include microbial preparations for animals.
6. The use according to claim 5, characterized in that: The animals include poultry, livestock or pets.
7. The use according to claim 5, characterized in that: The microbial preparations include oral preparations and / or external preparations.
8. The use according to claim 3, characterized in that: The Lactobacillus plantarum 6-14 is acid-resistant.
9. The use according to claim 3, characterized in that: The Lactobacillus plantarum 6-14 has bile salt resistance.
Citation Information
Patent Citations
Lactobacillus Plantarum ZN-3 and application thereof
CN107312726A
Lactobacillus plantarum-derived broad-spectrum antibacterial peptide and application thereof
CN112094323A
Lactobacillus plantarum YJ2406 and application thereof
CN115820498A
Preparation of swine lactobacillus plantarum fermentation liquor with antibacterial activity on various bacteria
CN117004523A
Lactobacillus plantarum capable of effectively inhibiting multi-drug-resistant klebsiella pneumoniae and application of lactobacillus plantarum
CN117467570A
Cited By
Phytobacterium plantarum YH001 with bacteriostatic activity as well as screening method and application thereof
CN120310676A
